Rituximab
Phase 2Completed 0 watching 0 views this week⚡ Active
52
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Kidney Transplantation
Conditions
Kidney Transplantation, Rituximab (RTx), Living Donors, Immunology, Virus
Trial Timeline
Jan 1, 2010 → Jun 18, 2019
NCT ID
NCT01136395About Rituximab
Rituximab is a phase 2 stage product being developed by Astellas Pharma for Kidney Transplantation. The current trial status is completed. This product is registered under clinical trial identifier NCT01136395. Target conditions include Kidney Transplantation, Rituximab (RTx), Living Donors.
Hype Score Breakdown
Clinical
17
Activity
12
Company
10
Novelty
5
Community
5
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT01136395 | Phase 2 | Completed |
Competing Products
20 competing products in Kidney Transplantation